199 related articles for article (PubMed ID: 28847765)
1. Acute disseminated candidiasis with skin lesions: a systematic review.
Guarana M; Nucci M
Clin Microbiol Infect; 2018 Mar; 24(3):246-250. PubMed ID: 28847765
[TBL] [Abstract][Full Text] [Related]
2. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of candidaemia and invasive candidiasis. A changing face.
Quindós G
Rev Iberoam Micol; 2014; 31(1):42-8. PubMed ID: 24270071
[TBL] [Abstract][Full Text] [Related]
4. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
[TBL] [Abstract][Full Text] [Related]
5. Single-center retrospective study of the incidence of, and risk factors for, non-C. albicans invasive candidiasis in hospitalized patients in China.
Wang L; Tong Z; Wang Z; Xu L; Wu Y; Liu Y; Wu L
Med Mycol; 2014 Feb; 52(2):115-22. PubMed ID: 24626056
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a risk model for identification of non-neutropenic, critically ill adult patients at high risk of invasive Candida infection: the Fungal Infection Risk Evaluation (FIRE) Study.
Harrison D; Muskett H; Harvey S; Grieve R; Shahin J; Patel K; Sadique Z; Allen E; Dybowski R; Jit M; Edgeworth J; Kibbler C; Barnes R; Soni N; Rowan K
Health Technol Assess; 2013 Feb; 17(3):1-156. PubMed ID: 23369845
[TBL] [Abstract][Full Text] [Related]
7. Weekly use of fluconazole as prophylaxis in haematological patients at risk for invasive candidiasis.
Vuichard D; Weisser M; Orasch C; Frei R; Heim D; Passweg JR; Widmer AF
BMC Infect Dis; 2014 Nov; 14():573. PubMed ID: 25384689
[TBL] [Abstract][Full Text] [Related]
8. [Skin lesions associated with invasive candidiasis in a neutropenic patient with acute myeloid leukemia].
Santarelli IM; Brest A; Juri PJ; Grinspun M; Fernández SI
Rev Fac Cien Med Univ Nac Cordoba; 2023 Jun; 80(2):158-159. PubMed ID: 37402301
[TBL] [Abstract][Full Text] [Related]
9. Invasive candidiasis in the neutropenic patient.
Fortún J; Gioia F
Rev Esp Quimioter; 2017 Sep; 30 Suppl 1():22-25. PubMed ID: 28882010
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
[TBL] [Abstract][Full Text] [Related]
11. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
12. The comparative efficacy of cilofungin, fluconazole and amphotericin B in disseminated Candida tropicalis infection in neutropenic mice.
Fong IW; Bannatyne RM; Cheng PC
Clin Invest Med; 1992 Oct; 15(5):434-9. PubMed ID: 1458716
[TBL] [Abstract][Full Text] [Related]
13. Breakthrough candidaemia in the era of broad-spectrum antifungal therapies.
Cuervo G; Garcia-Vidal C; Nucci M; Puchades F; Fernández-Ruiz M; Obed M; Manzur A; Gudiol C; Pemán J; Aguado JM; Ayats J; Carratalà J
Clin Microbiol Infect; 2016 Feb; 22(2):181-188. PubMed ID: 26460064
[TBL] [Abstract][Full Text] [Related]
14. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis.
Warn PA; Sharp A; Morrissey G; Denning DW
J Antimicrob Chemother; 2005 Sep; 56(3):590-3. PubMed ID: 16046462
[TBL] [Abstract][Full Text] [Related]
15. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
Charlier C; Hart E; Lefort A; Ribaud P; Dromer F; Denning DW; Lortholary O
J Antimicrob Chemother; 2006 Mar; 57(3):384-410. PubMed ID: 16449304
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology, antifungal susceptibilities, and risk factors for invasive candidiasis from 2011 to 2013 in a teaching hospital in southwest China.
Pu S; Niu S; Zhang C; Xu X; Qin M; Huang S; Zhang L
J Microbiol Immunol Infect; 2017 Feb; 50(1):97-103. PubMed ID: 25769664
[TBL] [Abstract][Full Text] [Related]
18. [Impact of antifungal prophylaxis on the gastrointestinal yeast colonisation in patients with haematological malignancies].
Rimek D; Redetzke K; Kappe R
Mycoses; 2006; 49 Suppl 2():18-23. PubMed ID: 17022757
[TBL] [Abstract][Full Text] [Related]
19. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model.
Ghannoum MA; Okogbule-Wonodi I; Bhat N; Sanati H
J Chemother; 1999 Feb; 11(1):34-9. PubMed ID: 10078778
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital.
Bedini A; Venturelli C; Mussini C; Guaraldi G; Codeluppi M; Borghi V; Rumpianesi F; Barchiesi F; Esposito R
Clin Microbiol Infect; 2006 Jan; 12(1):75-80. PubMed ID: 16460550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
